The Problem
A global pharma client was preparing simultaneous HTA submissions for a rare disease asset across the UK, Germany, and a third European market. The challenge was not capacity. It was structured.
Three country teams were building evidence packages in parallel, each with its own approach to comparator selection, data synthesis, and dossier formatting. The alignment was informal. Critical risks such as OS maturity gaps for G-BA's AMNOG process, comparator misalignment against NICE's single technology appraisal methodology, and ICER exposure relative to each country's reimbursement threshold were not surfacing until internal review cycles, often weeks before submission deadlines.
In a rare disease indication with a limited patient population, a failed or delayed submission carries consequences that go beyond timeline slippage. Commercial windows are narrow. Regulatory precedent matters. The reputational cost is real.
What Evalueserve Did
Evalueserve deployed PharmaHTAInsight as the evidence and risk intelligence backbone across all three submissions.
The platform's Evidence Intake agents aggregated SLR outputs, CSR data, and cross-jurisdiction HTA precedents into a single repository indexed by PICO framework. This replaced three separate evidence libraries with one auditable, searchable source.
A dedicated Risk Assessment agent ran pre-submission stress-tests for each country dossier: scoring comparator alignment against NICE methodology, flagging OS maturity gaps relevant to the AMNOG process, and modeling ICER sensitivity curves against each country's reimbursement threshold. Risks were scored and ranked before internal review, not during it.
Country-adapted dossiers were generated in GxP-ready format with full audit trails. Medical writers received structured, pre-validated evidence packages. Their work shifted from evidence of assembly to narrative quality, which is where the highest-value judgment belongs.
"The AI-assisted literature screening reduced the time our team spent on manual review while maintaining the scientific rigor and traceability we require for HTA submissions. By accelerating evidence synthesis and structuring data for downstream HEOR analyses, we were able to prepare our evidence package several weeks faster and focus more on strategic decision-making than administrative tasks."
The Results
Evidence synthesis time fell 38% across all three submissions. The pre-submission risk layer identified two comparator alignment issues that, left unaddressed, would have triggered formal objections from NICE assessors. Both were resolved before submission.
Dossier localization, previously running three parallel workstreams across three country teams, consolidated into a single agentic workflow. The operating model became more efficient and less exposed to cross-country inconsistency.
Following the engagement, the client extended PharmaHTAInsight to cover four additional pipeline assets entering market access planning.
Why This Matters
HTA submissions fail for two reasons: evidence gaps and process failures. The first is a science problem. The second is an operations problem. This engagement addressed the second at scale.
Parallel country teams working on the same asset in isolation will produce divergent dossiers. Manual review cycles will surface risks late. The cost of catching a comparator alignment issue after submission is categorically different from catching it three months before.
PharmaHTAInsight brings the intelligence layer into the submission process itself, not after it.
Talk to One of Our Experts
Get in touch today to find out about how Evalueserve can help you improve your processes, making you better, faster and more efficient.
Overview & Impact
A global pharma company needed to prepare simultaneous HTA submissions across three European markets without duplicating evidence work across country teams. PharmaHTAInsight unified evidence synthesis, surfaced submission risks earlier, and streamlined dossier development.